Boehringer Ingelheim and Cue Biopharma Collaborate to Develop Novel B Cell Depletion Therapy for Autoimmune Diseases
April 14, 2025 – Boehringer Ingelheim, a leading research-driven pharmaceutical company based in Ingelheim, Germany, and Cue Biopharma, Inc., a clinical-stage biopharmaceutical company headquartered in Boston, MA, USA, have announced a strategic research collaboration and license agreement. This collaboration aims to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases.
About Cue Biopharma and CUE-501
Cue Biopharma is a pioneering biotech company specializing in the development of a novel class of therapeutic biologics. Their innovative approach focuses on selectively engaging and modulating disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases. CUE-501 is one such promising product candidate, which utilizes the company’s proprietary CUE-Targeted Immune Modulation (CUE-TIM) technology.
The Collaboration and License Agreement
Under the terms of the agreement, Boehringer Ingelheim will gain exclusive rights to develop, manufacture, and commercialize CUE-501 globally. In return, Cue Biopharma will receive an upfront payment, potential milestone payments, and tiered royalties on net sales of the product. The collaboration also includes an option for Boehringer Ingelheim to expand the partnership to additional Cue Biopharma product candidates.
Impact on the Autoimmune Disease Community
For individuals living with autoimmune diseases, this collaboration represents a significant step forward in the development of more effective and targeted treatments. B cell depletion therapies have already shown success in managing certain autoimmune diseases, but the differentiated approach of CUE-501 could lead to improved efficacy and fewer side effects. This innovation could potentially change the lives of millions of people worldwide who are currently living with these debilitating conditions.
Global Implications
The impact of this collaboration extends beyond the autoimmune disease community. The successful development and commercialization of CUE-501 could pave the way for new advances in the field of immunotherapy and biologics. This collaboration between Boehringer Ingelheim and Cue Biopharma serves as a testament to the power of partnerships between industry leaders and innovative biotech companies in driving groundbreaking research and creating novel treatments for various diseases.
Conclusion
The strategic research collaboration and license agreement between Boehringer Ingelheim and Cue Biopharma marks an exciting milestone in the development of CUE-501, a differentiated B cell depletion therapy for autoimmune diseases. This partnership brings together the expertise and resources of a leading pharmaceutical company and a pioneering biotech company to create a potential game-changer in the treatment landscape for autoimmune diseases. The global implications of this collaboration could lead to significant advancements in the field of immunotherapy and biologics, ultimately benefiting patients and the scientific community as a whole.
- Boehringer Ingelheim and Cue Biopharma announce a strategic collaboration and license agreement to develop and commercialize CUE-501, a novel B cell depletion therapy for autoimmune diseases.
- Cue Biopharma is a clinical-stage biopharmaceutical company specializing in the development of therapeutic biologics to selectively engage and modulate disease-specific T cells.
- The collaboration grants Boehringer Ingelheim exclusive rights to develop, manufacture, and commercialize CUE-501 globally in exchange for upfront and milestone payments, and tiered royalties on net sales.
- The collaboration could lead to improved efficacy and fewer side effects for individuals with autoimmune diseases, ultimately changing the lives of millions of people.
- The partnership between Boehringer Ingelheim and Cue Biopharma serves as a testament to the power of industry-biotech collaborations in driving groundbreaking research and creating novel treatments.
